CALIFORNIA LIFE SCIENCES

BUD · Budget/Appropriations

Support full funding across HHS departments

CPT · Copyright/Patent/Trademark

Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem

MAN · Manufacturing

Support robust domestic supply chain development and manufacturing ecosystem

SMB · Small Business

Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs

SCI · Science/Technology

Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care

TAR · Tariff (miscellaneous tariff bills)

Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries

TRD · Trade (domestic/foreign)

Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment

LBR · Labor Issues/Antitrust/Workplace

Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry

HCR · Health Issues

Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user

MMM · Medicare/Medicaid

Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication

TAX · Taxation/Internal Revenue Code

Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit

MED · Medical/Disease Research/Clinical Labs

Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations